

## **PRESS RELEASE**

### **Dr. Ivan Labat Joins BioMarker Pharmaceuticals as Director of Research**

**San Jose, Calif., December 1, 2006** - BioMarker Pharmaceuticals, Inc., a privately held company focused on developing and manufacturing science-based pharmaceuticals, nutraceuticals, and diagnostics for the treatment and prevention of age-related disorders announced that Dr. Ivan Labat, PhD, will lead the company's research program as Sr. Director of Research and Product Development.

Dr. Labat has an extensive and successful career in commercial biotechnology with special expertise in computational biology, bioinformatics and genomics. He was one of the principal scientists at Hyseq Inc. (1994-2002) where he helped establish that company as one of the first successful companies in the newly emerging field of genomics. At Hyseq Dr. Labat was responsible for all of the company's R&D data integration & analysis as well as heading major international collaborations that included university and commercial biotechnology company partners. Prior to Hyseq, Dr. Labat worked at the U.S. Dept. of Energy's Argonne National Laboratory where he designed and developed algorithms and software for a highly innovative method of DNA sequencing by oligonucleotide hybridization (SBH). From 2003 to 2005 Dr. Labat served as President & CEO of Orion Biomedical, Inc., an early stage diagnostic biotechnology company dedicated to the development and commercialization of biomarkers for diagnostics and therapies enabling the personalized treatment of pregnancy-related disorders. He has also provided consulting services to several biotechnology companies in high-level information technology applications for integration of research with business applications.

Dr. Labat received his PhD in Molecular Biology and Physiology from the University of Belgrade, Belgrade, Yugoslavia. He has contributed several landmark research papers to the scientific literature in large-scale DNA sequencing approaches that were instrumental in completion of the international human gene mapping & sequencing program. He is also an inventor on over 40 patent applications.

"We are very excited to have Dr. Ivan Labat join us to lead our research effort," said Dr. Xi Zhao-Wilson, CEO & President of BioMarker Pharmaceuticals Inc. "Dr. Labat brings to our research team a deep knowledge of genomics-based technology as well as practical applications in the areas of diagnostics and product development. This will be a critical factor as BioMarker now moves aggressively into this commercial phase of development".

#### **About BioMarker Pharmaceuticals, Inc.**

BioMarker Pharmaceuticals, Inc. is a leading developer and manufacturer of science-based nutraceuticals and therapeutics designed to treat and prevent the chronic disorders associated with aging. Longevity therapeutics have the potential for greatly extending a normal and healthy lifespan. The company's products are based on activating the genes and proteins responsible for increased longevity in the only scientifically proven model that shows increased lifespan results from a severe reduction in calories (caloric restriction). BioMarker uses advanced DNA-based technology to identify interventions that can substitute for and mimic the effects of caloric restriction. The company, headquartered in San Jose, Calif., holds worldwide, exclusive licenses to patents for identifying calorie restriction mimetics. For more information about BioMarker Pharmaceuticals, Inc., please visit the company's Web site at [www.biomarkerinc.com](http://www.biomarkerinc.com).

#### **FOR FURTHER INFORMATION:**

Paul Watkins, VP of Business Development  
BioMarker Pharmaceuticals, Inc.  
5941 Optical Court  
San Jose, CA 95008  
Tel: 408-257-2000  
Fax: 408-356-6661  
Email: [press@biomarkerinc.com](mailto:press@biomarkerinc.com)